appScorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Laurus Labs Ltd
LAURUSLABS
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key MetricsEdit
Forecast & RatingsDetailed Forecast
Analysts have suggested that investors can buy this stock
Company Profile
Laurus Labs Private Ltd is a research and development pharmaceutical company which manufactures active pharmaceutical ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.
Investor PresentationView older
View Older PresentationsPeersCompare with peers
Sun Pharmaceutical Industries Ltd
Cipla Ltd
Zydus Lifesciences Ltd
Dr Reddy's Laboratories Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Financial TrendFinancial statements
Holdings TrendDetailed holdings
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Increased Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has increased by 1.10%
Recent NewsAll news
Healthcare at new high; Lupin, Glenmark among 5 stocks for up to 15% upside
10 hours ago•Business Standard
Volumes spurt at Laurus Labs Ltd counter
2 days ago•Business Standard
Laurus Labs Ltd up for third consecutive session
3 days ago•Business Standard
Laurus Labs edges lower after CARE Ratings downgrades rating outlook to ‘negative’
2 weeks ago•Business Standard
Brokerage Views: Citi On Ambuja Cements, Laurus Labs And More
3 weeks ago•Bloomberg Quint
Laurus Labs Ltd spurts 0.12%, gains for fifth straight session
3 weeks ago•Business Standard
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant